RxDoctor Payments Data

Asad Jadoon, MD

Cardiovascular Disease · Richmond, KYNPI 1932101771

Payments from drug & device makers

$1,252in general payments, 2019–2025

Across 66 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$419
  • Novartis$195
  • Abbott$121
  • Bayer$85
  • Kestra Medical Technology Services, Inc.$82
  • Boehringer Ingelheim$69
  • plus $279 from 11 others

What the payments were for

  • Food & beverage$1,16693%
  • Education$857%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,252 in reported general payments places this provider in the 30th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$705,764
Medicare patients
432
Services billed
102,234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban381$368,031
EntrestoSacubitril/Valsartan178$229,624
XareltoRivaroxaban50$50,915
MultaqDronedarone Hcl26$38,669
VerquvoVericiguat22$32,466
InpefaSotagliflozin28$32,287
JardianceEmpagliflozin23$29,544
FarxigaDapagliflozin Propanediol28$23,848
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$18,131
BrilintaTicagrelor17$12,183
Metoprolol Succinate809$9,534
Breo ElliptaFluticasone/Vilanterol13$8,399
Rosuvastatin Calcium478$4,957
Amiodarone Hcl29$2,544
Dabigatran EtexilateDabigatran Etexilate Mesylate13$2,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$368,031381 claims
NovartisEntresto$195$229,624178 claims
MerckVerquvo$419$32,46622 claims
Lexicon Pharmaceuticals, Inc.Inpefa$57$32,28728 claims
Boehringer IngelheimJardiance$69$29,54423 claims
GSKTrelegy Ellipta, Breo Ellipta$16$26,53037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 258 cardiovascular disease providers in Kentucky.

Other cardiovascular disease in Richmond

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →